Occam's Strategic Partnership with Geron Continues with the Placement of Head of R&D
In November 2024, Joseph Eid, MD, was placed by Occam Global as Executive Vice President, Research and Development of Geron Corporation (Nasdaq: GERN), a commercial-stage oncology biopharma.
In this role, Dr. Eid will lead the Research and Development department for the organization, including medical, clinical, and safety/pharmacovigilance teams. He will drive innovative strategies to support the commercial success of RYTELO™ and ensure ongoing research opportunities.
Dr. Eid has over twenty years of experience in medical affairs and clinical development in the biopharmaceutical industry. Recently, he led medical affairs and research at Dragonfly Therapeutics as President of Research and Development. Previously, he served as Executive Vice President and Chief Medical Officer at Luzsana Bio, a subsidiary of Hengrui Pharmaceuticals. Dr. Eid began his career in oncology drug development at Roche in 2004 before joining Merck in 2009.
Dr. Eid’s appointment marks Occam’s eighth high-profile executive placements, including the Chief Commercial Officer, Chief Financial Officer, Chief Legal Officer, Chief Business Officer, and three Board members. Geron exemplifies Occam Global as a long-term strategic partner for a public biotech company rebuilding for the commercial stage. Read more about Occam's work with Geron in our case study.
Recent Placements
Occam Global is a trusted executive search, consulting, and investment partner for leaders and investors shaping the future of life sciences, deep tech, and venture capital. Since 2012, we’ve helped build high-performing teams and advised visionary companies from stealth to public markets. Our success stems from exceptional access to rare talent, deep sector expertise, and a commitment to results guided by elevated ethics and enlightened aggression.